Robert Hugin
Robert Hugin is a former CEO of Celgene who oversaw the launch and commercialization of Revlimid. He has been a controversial figure due to the company's pricing strategies, which have drawn criticism for making the drug unaffordable for many patients.
Global Media Ratings
Countries Mentioned
No country-level mention data available.
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
United States:
Robert Hugin, who worked as Celgene’s CEO and then executive chairman, received $51 million in total compensation from 2015 to 2017.
4